CLOVER HEALTH INVESTMENTS CORP CLA (CLOV)
Health Care · Managed Health Care · NASDAQ
Clover Health combines Medicare Advantage insurance with a data-driven, AI-enabled software platform designed to improve primary care outcomes and manage medical costs.
What CLOVER HEALTH INVESTMENTS CORP CLA does
Clover Health is a healthcare company that provides Medicare Advantage insurance plans and utilizes its proprietary AI-powered platform, Clover Assistant, to support primary care physicians in managing patient health. The company also offers its technology to external payors and providers through its Counterpart Assistant software brand.
Themes: Medicare Advantage, AI-driven healthcare, Value-based care technology, Health insurance software
Fundamentals
- Price$4.15 as of 2026-08-21 close
- Market cap$2.4B as of 2026-08-24
- 1-year return+59.0% 2025-08-21 close $2.61 → 2026-08-21 close $4.15
- P/En/a negative earnings
- Net margin-2.6% as of 2026-08-24
- ROE-17.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+48.8% as of 2026-08-24
- Revenue CAGR (3y)+20.6% SEC XBRL
- Beta2.51 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How CLOV compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CLOV is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
43.2 #1233 of 1,704 scored · #199 of 240 in Health Care
Volume and participation 57th: it gapped 30.6% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; momentum 56th: near the bottom of its 14-day range (oversold); weakest is trend 27th: the price is 7% below the average price paid over the period covered, so the typical buyer over that stretch is under water.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How CLOVER HEALTH INVESTMENTS CORP CLA looks technically
CLOVER HEALTH INVESTMENTS CORP CLA (CLOV) is trading 36.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 55 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 25.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 36.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +36.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.66 | $4.66 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.05 | $3.05 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 5.19. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 55 trading days ago — a "golden cross", a bullish long-term signal | 55 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 43.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($4.08 to $5.19) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 5.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.59 | $5.59 |
|---|---|---|
| From the 52-week high | it is 25.8% below its 52-week high (its highest price of the past year) | -25.8% |
| Above the 52-week low | it is 162.7% above its 52-week low (its lowest price of the past year) | +162.7% |
| Below the 52-week high | it is 25.8% below its highest point of the past year | 25.8% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 40 trading days ago | 40 sessions |
| All-time high | its highest closing price on record is $28.85 (set on 2021-06-09) | $28.85 |
| Given back of the 52-week move | over the past year its closes ranged ($1.70 to $5.41), and it has given back roughly a third of its rise from last year’s low — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.00 to $3.12. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.0% |
| From the all-time high | it is 85.6% below its all-time high | -85.6% |
| Nearest price level | it is trading 0.7% above a support level at $4.12 — a price it turned at twice since 2026-07-28, most recently on 2026-08-05. Since 2024-08-21 it has 10 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.7% |
| All-time low | its lowest closing price on record is $0.606 (set on 2024-04-22) | $0.606 |
| Above the all-time low | it is 584.8% above its all-time low | +584.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 83% of it) | 17th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2482 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2482 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.99 and $4.72 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.99 – $4.35 – $4.72 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges above its 200-day average price (36.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.60× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 30.6% above the previous close 49 sessions ago and has not traded back through the level it left behind at 3.92 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +30.6% |
| Gap filled | a 18.1% gap up opened on 2026-08-06 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 10 sessions to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 15.7 percentage points (the stock lost 13.4% while the market gained 2.3%) | -15.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 12.2 percentage points (the stock gained 15.3% while the market gained 3.1%) | +12.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 94.4 percentage points (the stock gained 105.4% while the market gained 11.1%) | +94.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 38.5 percentage points (the stock gained 59.0% while the market gained 20.5%) | +38.5% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 17.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 28% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.23 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +28.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is under water. That average is $4.46 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -6.8% |
Price levels it has turned at before
CLOV last closed at $4.15 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.12 | Support | 0.7% below the last close | turned there twice · 2026-07-28 to 2026-08-05 |
| $4.26 | Resistance | 2.6% above the last close | turned there twice · 2024-10-04 to 2026-05-28 |
| $3.91 | Support | 5.8% below the last close | turned there three times · 2025-03-25 to 2025-10-24 |
| $3.68 | Support | 11.3% below the last close | turned there twice · 2024-10-23 to 2026-05-14 |
| $4.85 | Resistance | 16.9% above the last close | turned there three times · 2025-01-24 to 2026-07-21 |
| $5.18 | Resistance | 24.9% above the last close | turned there twice · 2026-06-11 to 2026-08-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $5.19.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.33 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$5.17 range $5.00 – $5.50; median $5.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CLOV
- Consensus EPS estimate$0.01 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory and legislative risks related to the Patient Protection and Affordable Care Act (ACA), Medicare policy, and medical loss ratios.","Dependency on the successful adoption and effectiveness of the Clover Assistant and Counterpart Assistant AI platforms.","Risk of failing to maintain or improve Star Ratings, which significantly impacts financial performance and member retention."]
What changed in the latest 10-Q
AI-assisted comparison of CLOV's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) adds 'Total PMPM' and 'Consolidated' section to key financial measures table with consolidated revenue, medical claims, gross profit, and adjusted metrics for Q1 2026 and Q1 2025
- Newer filing adds 'Consolidated Gross profit' metric ($159,541 for Q1 2026; $108,889 for Q1 2025)
- Newer filing adds reference to consolidated financial statements 'for the year ended December 31, 2025, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on February 27, 2026'
- Newer filing updates membership count to '155,773 members' at March 31, 2026 and updates county count to '203 counties'
- Newer filing adds 'Total revenues' definition section explaining that Total revenues = Premiums earned, net + Other income
- Removed:
- Older filing (2025-11-07) contains 'Recent Developments' section with CMS Star Ratings announcement dated October 9, 2025 regarding 3.5 Stars for PPO plans and 4.0 Stars for HMO plan - removed in newer filing
- Older filing includes 'Nine Months Ended September 30' comparison data in key financial measures table - removed in newer filing
- Older filing references 'year ended December 31, 2024, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the "SEC") on March 3, 2025' - replaced in newer filing
- Older filing lists separate 'Premiums earned, gross' and 'Premiums earned, net' metrics with gross and net benefits expense ratios - consolidated differently in newer filing
- Older filing includes 'Normalized benefits expense ratio' metrics - not present in newer filing
- Older filing references 'Corporate/Other' segment - not mentioned in newer filing version
- Reworded:
- Membership date updated from 'September 30, 2025' with '109,226 members' and '200 counties' to 'March 31, 2026' with '155,773 members' and '203 counties'
- Reporting period changed from 'three and nine months ended September 30, 2025' to 'three months ended March 31, 2026'
- Key Performance Measures table structure reorganized: newer filing presents 'Consolidated' and 'Insurance Segment' sections separately with different metrics; older filing presented Insurance-specific metrics with gross/net distinctions
- Insurance segment reporting changed: newer filing shows 'Average Medicare Advantage membership' and 'Insurance Benefits Expense Ratio' at 86.5% for Q1 2026; older filing showed 'Insurance members at period end' with separate gross and net benefits ratios at 93.5% and 92.4% for Q3 2025
- Newer filing replaces 'Insurance medical claim expense incurred, gross' and 'Insurance net medical claims incurred' with single 'Insurance Net medical claims incurred' metric ($610,001 for Q1 2026)
- Newer filing removes 'Adjusted Net income from continuing operations' label and shows 'Adjusted Net income' instead
- Notes:
- The two filings report different quarterly periods (Q1 2026 vs Q3 2025) with different comparison years, making direct metric continuity assessment difficult
- Older filing text appears truncated at end ('allows us to evaluate our underwriting performance without regar') - comparison of 'Premiums earned' section definitions may be incomplete
- Table formatting and column organization differs significantly between filings, suggesting possible restructuring of financial presentation rather than simple data updates
Risk Factors
- Added:
- Added bullet point: 'geopolitical uncertainty and instability' (filed 2026-05-08)
- Removed:
- Removed phrase 'serving the Medicare eligible population' from Counterpart Assistant description (filed 2025-11-07)
- Removed 'our Insurance business' reference, replaced with generic business development language (filed 2025-11-07)
- Removed 'our beneficiary base' phrasing (filed 2025-11-07)
- Removed 'medical expenses and' before 'medical loss ratios' (filed 2025-11-07)
- Removed 'persistent high' modifier before 'inflation' (filed 2025-11-07)
- Removed 'and' before final bullet point, changed to semicolon format (filed 2025-11-07)
- Reworded:
- Changed 'condensed consolidated subsidiaries' to 'consolidated subsidiaries' in company definition (filed 2026-05-08)
- Changed 'our Insurance business' to 'our business' in development and management bullet point (filed 2026-05-08)
- Changed 'our beneficiary base' to 'our member base' in network management bullet point (filed 2026-05-08)
- Changed 'and' to semicolon before 'persistent high inflation' bullet point, and removed 'persistent high' modifier, leaving only 'inflation and fluctuating interest rates' (filed 2026-05-08)
- Expanded geopolitical risk reference from implicit to explicit with new standalone bullet point (filed 2026-05-08)
- Notes:
- Both filings are truncated at similar points in the Channels for Disclosure section, limiting assessment of any later changes
- Page number references changed (33-35 in newer vs 39-41 in older), consistent with content reorganization rather than substantive changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 16 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 16 sells ($4M) — 6 selling insiders
- Last 180 days0 buys · 18 sells ($4M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-20. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CLOV's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CLOV as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 48,172,570
- Reported value $84,783,723
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CLOV had 28,237,098 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for CLOV because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 28,237,098
- Prior settlement (shares) 28,748,883
- Reported change -1.78%
- Days to cover (reported) 7.18
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CLOV vs…
Frequently asked questions
What does CLOVER HEALTH INVESTMENTS CORP CLA (CLOV) do?
Clover Health is a healthcare company that provides Medicare Advantage insurance plans and utilizes its proprietary AI-powered platform, Clover Assistant, to support primary care physicians in managing patient health. The company also offers its technology to external payors and providers through its Counterpart Assistant software brand.
What sector is CLOVER HEALTH INVESTMENTS CORP CLA (CLOV) in?
CLOVER HEALTH INVESTMENTS CORP CLA (CLOV) is classified in the Health Care sector. Its industry is Managed Health Care. It trades on NASDAQ.
Who are CLOVER HEALTH INVESTMENTS CORP CLA's (CLOV) competitors?
Notable peers of CLOVER HEALTH INVESTMENTS CORP CLA (CLOV) include UnitedHealth Group, Humana, CVS Health, Elevance Health and Centene. This peer set is informational only — not financial advice.
Is CLOVER HEALTH INVESTMENTS CORP CLA (CLOV) overbought or oversold right now?
CLOVER HEALTH INVESTMENTS CORP CLA (CLOV) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CLOV come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.